Muhammed Hasan, MD

Muhammed Hasan, MD

Medical Director Center for Interventional Endoscopy

Digestive Health and Surgery

Muhammed Hasan

Overview

Dr. Muhammad K. Hasan is the Director of Advanced Endoscopy Fellowship Program at Center for Interventional Endoscopy. He received his medical degree from Allama Iqbal Medical College Lahore, Pakistan. He is board certified in gastroenterology and internal medicine. Dr Hasan completed his residency at the University of Oklahoma, Oklahoma City where he also served as a Chief Medical Resident for a year. After that, he completed his gastroenterology fellowship training in 2008 at the same institution. Then, Dr Hasan went to Mayo Clinic Jacksonville and completed training in advanced endoscopy and endoscopic ultrasound (EUS). Afterwards he moved to Medical University of South Carolina and attained another year of advanced endoscopy training in ERCP and worked as instructor in Internal Medicine. Dr Hasan joined AdventHealth Orlando in 2010 and helped develop the Center for Interventional Endoscopy. He has dedicated his practice towards advanced and complex endoscopy. He specializes in the treatment of Barrett’s esophagus, endoscopic resection of polyps (EMR and ESD), double balloon enteroscopy, Zenker's diverticulectomy, pancreatic and biliary disorders with particular expertise in Therapeutic ERCP and interventional Endoscopic Ultrasound (EUS). He has authored many professional articles and book chapters. He also actively participates in many national and international conferences for invited lectures and endoscopy workshops.
Conditions Treated: Gastrointestinal cancer Pancreatic disorders Biliary disorders Barrett’s esophagus Gastrointestinal polyps Gastrointestinal bleeding
Procedures: Colonoscopy EGD – esophagogastroduodenoscopy ERCP – Endoscopic Retrograde CholangioPancreatography EUS – Endoscopic Ultrasound Deep Enteroscopy Radiofrequency and Cryoablation for Barrett’s esophagus ESD - Endoscopic Submucosal Dissection POEM - Peroral Endoscopic Myotomy Cricopharyngeal Myotomy for Zenker’s Diverticulum

Articles

Biliary drainage: role of EUS guidance

GASTROINTESTINAL ENDOSCOPY

2016

A Rare Case of Pancreas Pseudodivisum

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

2015

Primary Pancreatic Ewing's Sarcoma with Portal Vein Tumor Thrombosis

JOURNAL OF GASTROINTESTINAL SURGERY

2013

Endoscopic Ultrasound-Guided Fine Needle Aspiration in Cystic Pancreatic Lesions

CLINICAL ENDOSCOPY

2012

More Publication Information

Education & Training

Education

Allama Iqbal Medical College

Residency

University of Oklahoma, Oklahoma City

Fellowship

University of Oklahoma; Mayo Clinic Jacksonville; University of Oklahoma College of Medicine; Medical University of South Carolina College of Medicine

Specialty

Gastroenterology

Board Certifications

American Board of Gastroenterology

Associated Clinical Trials

NCT03398135

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

Icon for trial | M16-066 A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16

This study is currently enrolling.

The purpose of this study is to evaluate the efficacy and safety of Risankizumab versus placebo and determine how well it works as maintenance therapy and long-term therapy for subjects with moderate to severe ulcerative coliti ...

NCT02914561

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

Icon for trial | GS-US-419-3895 Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

This study is currently enrolling.

You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgot ...

NCT03466411

A Phase 3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Subject with Moderately to Severely Active Crohn’s Disease

Icon for trial | CNTO1959CRD3001 A Phase 3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Subject with Moderately to Severely Active Crohn’s Disease

This study is currently enrolling.

There are 3 separate studies being described in this form. All 3 studies have the same primary purposes, but there are some small differences between GALAXI 1 (which is a Phase 2 study) and GALAXI 2 & 3 (which are identical ...

NCT04583358

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

Icon for trial | AMT-101-202 A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

This study is currently enrolling.

AMT-101 is being developed for use in patients with ulcerative colitis. We hope to learn how safe and beneficial this investigational drug is in research participants with ulcerative colitis. “Investigational” means that the dr ...